|
|
|
Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 117-123
|
|
Should HER2 status be routinely measured for all breast cancer patients?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ADJUVANT THERAPY;
ARTICLE;
BREAST CANCER;
CANCER PATIENT;
DIAGNOSTIC TEST;
DRUG EFFECT;
DRUG EFFICACY;
FLUORESCENCE IN SITU HYBRIDIZATION;
HUMAN;
IMMUNOCYTOCHEMISTRY;
ONCOGENE NEU;
PRIORITY JOURNAL;
PROGNOSIS;
SCORING SYSTEM;
STANDARDIZATION;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
GENE EXPRESSION;
HUMANS;
PROGNOSIS;
RECEPTOR, ERBB-2;
|
|
EID: 0032851670
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (42)
|
|
References (28)
|
